Skip to main content
AmigoFish

Episode 521: ESMO 2026 - Reconciling Discrepant Results of Neoadjuvant Chemotherapy + IO in MIBC

From The Uromigos · · 32 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Rob Jones joins the show to discuss two phase 3 trials from ESMO 2026 which did not show benefit from chemotherapy + IO vs chemo in MIBC. We discuss the wider implications incorporating the NIAGARA data and in light of neo/adjuvant EVP.

Back to The Uromigos · Report a problem